AbTis | 앱티스 Alternatives & Competitors
12 companies similar to AbTis | 앱티스 — Bridging Life and Science with Innovative Linker Technology
Companies similar to AbTis | 앱티스
ADC Biotechnology
Accelerating solutions for developers to overcome conjugation challenges, making new ADC-b...
ABIONYX Pharma
A New Generation Biotech Company
NBE-Therapeutics AG
Next generation antibody drug conjugates
Prescient Therapeutics
A clinical stage oncology company developing personalised medicine approaches to cancer; c...
Track all AbTis | 앱티스 competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Ablexis, LLC
A superior, next generation transgenic platform.
Mythic Therapeutics, Inc.
Charting a new dimension in ADC technology
i2o Therapeutics
Boston-based biotech startup developing novel biologic therapies
SCOHIA PHARMA
Dedicated to advancing patient care with swift, innovative solutions in renal and metaboli...
Pinteon Therapeutics
Pioneering therapies targeting Pin1 to normalize disease processes and enhance patient out...
ILYA Pharma
Ilya Pharma 🇸🇪🇺🇸 is bringing local-acting immunotherapies to patients
About AbTis | 앱티스
AbTis Co., Ltd. is a leading ADC Biotech Company based in Korea South, founded in 2016. Known for its slogan "ADC 플랫폼 및 파이프라인 개발" which translates to "ADC platform and pipeline development," the company boasts of world-class platform technology.
ADC, Biotech, Platform Technology, Drug Development, Pharmaceuticals, Innovation, Biopharmaceuticals, Targeted Therapies
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches AbTis | 앱티스 and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at AbTis | 앱티스 on 11 Sep 2024. The 12 companies listed here were last checked between 17 Jun 2024 and 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.